Getinge (OTCMKTS:GNGBY) Upgraded at Zacks Research

Zacks Research upgraded shares of Getinge (OTCMKTS:GNGBY) to a hold rating in a research note issued to investors on Thursday morning,Zacks.com reports.

Getinge Trading Up 1.2%

OTCMKTS GNGBY opened at $20.69 on Thursday. The company has a market capitalization of $5.64 billion, a price-to-earnings ratio of 24.06 and a beta of 1.10. The firm’s fifty day moving average price is $20.89 and its 200 day moving average price is $22.20. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.32 and a quick ratio of 0.86. Getinge has a 12 month low of $18.70 and a 12 month high of $24.67.

Getinge (OTCMKTS:GNGBY) last issued its quarterly earnings data on Tuesday, January 27th. The company reported $0.47 earnings per share for the quarter. The firm had revenue of $1.08 billion for the quarter. Getinge had a net margin of 6.54% and a return on equity of 10.60%. On average, sell-side analysts expect that Getinge will post 1.26 earnings per share for the current fiscal year.

Getinge Company Profile

Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.

The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.